Financial Ratios Boston Scientific Corporation
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.02 USD | +0.98% |
|
-0.69% | +11.98% |
| 11-06 | Elutia Q3 revenue falls short of estimates, gross margin improves | RE |
| 11-03 | Tranche Update on Boston Scientific Corporation's Equity Buyback Plan announced on December 14, 2020. | CI |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.3 | 3.99 | 3.93 | 4.47 | 5.03 | |||||
Return on Total Capital | 2.87 | 4.92 | 4.79 | 5.39 | 6.02 | |||||
Return On Equity % | -0.56 | 6.52 | 4.08 | 8.58 | 8.89 | |||||
Return on Common Equity | -0.79 | 6.17 | 3.75 | 8.52 | 9.03 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 68.53 | 69.32 | 68.44 | 69.16 | 68.41 | |||||
SG&A Margin | 37.69 | 36.06 | 35.64 | 36.45 | 35.73 | |||||
EBITDA Margin % | 22.72 | 26.09 | 24.99 | 25.37 | 25.5 | |||||
EBITA Margin % | 19.35 | 23.13 | 22.36 | 22.79 | 23.04 | |||||
EBIT Margin % | 11.39 | 16.9 | 16.03 | 16.97 | 17.93 | |||||
Income From Continuing Operations Margin % | -0.83 | 8.76 | 5.5 | 11.17 | 11.02 | |||||
Net Income Margin % | -0.83 | 8.76 | 5.5 | 11.18 | 11.07 | |||||
Net Avail. For Common Margin % | -1.16 | 8.29 | 5.06 | 11.03 | 11.06 | |||||
Normalized Net Income Margin | 4.7 | 8.61 | 7.53 | 9.3 | 10.34 | |||||
Levered Free Cash Flow Margin | 12.32 | 23.3 | 9.11 | 13.2 | 10.79 | |||||
Unlevered Free Cash Flow Margin | 14.59 | 25.09 | 11.42 | 14.37 | 11.93 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.32 | 0.38 | 0.39 | 0.42 | 0.45 | |||||
Fixed Assets Turnover | 4 | 4.55 | 4.6 | 4.65 | 4.76 | |||||
Receivables Turnover (Average Receivables) | 5.9 | 7.19 | 6.77 | 6.78 | 7 | |||||
Inventory Turnover (Average Inventory) | 2.13 | 2.46 | 2.3 | 2.02 | 2 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.82 | 1.48 | 1.51 | 1.32 | 1.08 | |||||
Quick Ratio | 0.89 | 0.87 | 0.76 | 0.63 | 0.46 | |||||
Operating Cash Flow to Current Liabilities | 0.41 | 0.44 | 0.4 | 0.51 | 0.54 | |||||
Days Sales Outstanding (Average Receivables) | 62.01 | 50.8 | 53.94 | 53.8 | 52.3 | |||||
Days Outstanding Inventory (Average Inventory) | 171.86 | 148.17 | 158.52 | 180.84 | 183.14 | |||||
Average Days Payable Outstanding | 66.76 | 61.07 | 70.94 | 65.74 | 61.98 | |||||
Cash Conversion Cycle (Average Days) | 167.11 | 137.9 | 141.51 | 168.9 | 173.46 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 62.73 | 57.3 | 53.17 | 48.99 | 51.03 | |||||
Total Debt / Total Capital | 38.55 | 36.43 | 34.71 | 32.88 | 33.79 | |||||
LT Debt/Equity | 62.19 | 55.31 | 52.71 | 45.88 | 42.58 | |||||
Long-Term Debt / Total Capital | 38.22 | 35.16 | 34.41 | 30.8 | 28.19 | |||||
Total Liabilities / Total Assets | 50.2 | 48.43 | 45.88 | 44.42 | 44.15 | |||||
EBIT / Interest Expense | 3.13 | 5.89 | 4.33 | 9.12 | 9.84 | |||||
EBITDA / Interest Expense | 6.49 | 9.36 | 6.94 | 14 | 14.32 | |||||
(EBITDA - Capex) / Interest Expense | 5.45 | 7.74 | 5.69 | 11.31 | 11.73 | |||||
Total Debt / EBITDA | 4.1 | 2.98 | 2.87 | 2.58 | 2.57 | |||||
Net Debt / EBITDA | 3.36 | 2.38 | 2.58 | 2.35 | 2.48 | |||||
Total Debt / (EBITDA - Capex) | 4.89 | 3.61 | 3.5 | 3.19 | 3.14 | |||||
Net Debt / (EBITDA - Capex) | 4 | 2.88 | 3.15 | 2.9 | 3.02 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -7.66 | 19.92 | 6.68 | 12.29 | 17.61 | |||||
Gross Profit, 1 Yr. Growth % | -10.99 | 21.32 | 6.78 | 13.48 | 16.33 | |||||
EBITDA, 1 Yr. Growth % | -20.06 | 37.74 | 8.64 | 14.01 | 18.21 | |||||
EBITA, 1 Yr. Growth % | -23.43 | 43.38 | 10.57 | 14.42 | 18.89 | |||||
EBIT, 1 Yr. Growth % | -37.49 | 77.94 | 11.46 | 18.89 | 24.2 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -101.74 | -1.37K | -32.95 | 127.94 | 15.95 | |||||
Net Income, 1 Yr. Growth % | -101.74 | -1.37K | -32.95 | 128.08 | 16.38 | |||||
Normalized Net Income, 1 Yr. Growth % | -43.94 | 119.87 | 5.16 | 38.65 | 30.72 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -102.44 | -950.03 | -34.96 | 138.42 | 16.82 | |||||
Accounts Receivable, 1 Yr. Growth % | -16.25 | 16.13 | 10.8 | 13.1 | 14.81 | |||||
Inventory, 1 Yr. Growth % | -14.44 | 19.17 | 15.96 | 33.05 | 13.12 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 5.26 | 5.7 | 5.4 | 16.45 | 13.49 | |||||
Total Assets, 1 Yr. Growth % | 0.69 | 4.72 | 0.74 | 8.21 | 12.12 | |||||
Tangible Book Value, 1 Yr. Growth % | -83.17 | 110.66 | -17.8 | -13.53 | 80.78 | |||||
Common Equity, 1 Yr. Growth % | 10.44 | 8.46 | 5.72 | 9.73 | 12.9 | |||||
Cash From Operations, 1 Yr. Growth % | -17.86 | 24.01 | -18.4 | 64.02 | 37.24 | |||||
Capital Expenditures, 1 Yr. Growth % | -18.44 | 47.34 | 6.14 | 20.92 | 11.11 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -11.91 | 126.82 | -56.48 | 62.79 | -3.85 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -13.98 | 106.18 | -49.47 | 41.21 | -2.32 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 0.46 | 5.23 | 13.11 | 9.45 | 14.91 | |||||
Gross Profit, 2 Yr. CAGR % | -1.44 | 3.91 | 14.06 | 10.08 | 14.89 | |||||
EBITDA, 2 Yr. CAGR % | -7.25 | 4.47 | 23.58 | 11.29 | 16.09 | |||||
EBITA, 2 Yr. CAGR % | -9.13 | 4.26 | 27.63 | 12.48 | 16.63 | |||||
EBIT, 2 Yr. CAGR % | -19.08 | 4.75 | 46.13 | 15.11 | 21.52 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -77.85 | -52.94 | 191.76 | 23.63 | 62.63 | |||||
Net Income, 2 Yr. CAGR % | -77.85 | -52.94 | 191.76 | 23.66 | 62.98 | |||||
Normalized Net Income, 2 Yr. CAGR % | -29.17 | 9.99 | 64.02 | 20.75 | 34.66 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -73.88 | -54.48 | 135.13 | 24.53 | 66.89 | |||||
Accounts Receivable, 2 Yr. CAGR % | -2.42 | -1.38 | 13.43 | 11.94 | 13.95 | |||||
Inventory, 2 Yr. CAGR % | 7.64 | 0.98 | 17.56 | 24.21 | 22.68 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 19.44 | 5.48 | 5.55 | 10.79 | 14.96 | |||||
Total Assets, 2 Yr. CAGR % | 21.06 | 2.69 | 2.71 | 4.41 | 10.15 | |||||
Tangible Book Value, 2 Yr. CAGR % | -63.02 | -40.47 | 31.59 | -15.69 | 23.37 | |||||
Common Equity, 2 Yr. CAGR % | 32.53 | 9.44 | 7.08 | 7.7 | 11.3 | |||||
Cash From Operations, 2 Yr. CAGR % | 120.56 | 0.92 | 0.6 | 15.69 | 50.03 | |||||
Capital Expenditures, 2 Yr. CAGR % | 9.08 | 9.62 | 25.05 | 13.29 | 15.91 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 51.37 | 40.56 | 1.98 | -15.83 | 25.11 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 45.48 | 32.56 | 4.13 | -15.53 | 17.45 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 3.09 | 6.57 | 5.71 | 12.83 | 12.1 | |||||
Gross Profit, 3 Yr. CAGR % | 1.78 | 5.63 | 4.38 | 13.87 | 12.12 | |||||
EBITDA, 3 Yr. CAGR % | -2.68 | 5.82 | 3.7 | 20.3 | 13.55 | |||||
EBITA, 3 Yr. CAGR % | -3.94 | 5.79 | 3.88 | 23.07 | 14.58 | |||||
EBIT, 3 Yr. CAGR % | -10.95 | 5.23 | 3.55 | 36.42 | 18.07 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -7.62 | -14.59 | -47.04 | 168.71 | 21.04 | |||||
Net Income, 3 Yr. CAGR % | -7.62 | -14.59 | -47.04 | 168.77 | 21.21 | |||||
Normalized Net Income, 3 Yr. CAGR % | -17.73 | 3.32 | 4.11 | 55.08 | 24.01 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 2.26 | -16.61 | -48.73 | 136.22 | 21.9 | |||||
Accounts Receivable, 3 Yr. CAGR % | -0.37 | 3.41 | 2.52 | 13.32 | 12.89 | |||||
Inventory, 3 Yr. CAGR % | 7.81 | 11.35 | 5.74 | 22.51 | 20.4 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 14.42 | 14.67 | 5.45 | 9.07 | 11.68 | |||||
Total Assets, 3 Yr. CAGR % | 17.36 | 15.35 | 2.03 | 4.51 | 6.92 | |||||
Tangible Book Value, 3 Yr. CAGR % | -49.28 | -33.95 | -33.71 | 14.4 | 7.75 | |||||
Common Equity, 3 Yr. CAGR % | 29.78 | 23.96 | 8.19 | 7.95 | 9.41 | |||||
Cash From Operations, 3 Yr. CAGR % | 1.88 | 82.04 | -5.98 | 18.4 | 22.47 | |||||
Capital Expenditures, 3 Yr. CAGR % | 5.63 | 20.58 | 8.45 | 23.66 | 12.56 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -0.73 | 73.22 | -6.25 | 19.19 | -12.01 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 1.31 | 63.41 | -5.15 | 15.26 | -11.34 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 5.8 | 7.23 | 6.99 | 7.71 | 9.3 | |||||
Gross Profit, 5 Yr. CAGR % | 5.08 | 6.77 | 6.14 | 7.09 | 8.46 | |||||
EBITDA, 5 Yr. CAGR % | 4.02 | 7.06 | 5.34 | 6.65 | 8.49 | |||||
EBITA, 5 Yr. CAGR % | 3.98 | 7.27 | 5.56 | 6.91 | 8.8 | |||||
EBIT, 5 Yr. CAGR % | 0.84 | 7.63 | 4.92 | 6.99 | 10.39 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -19.26 | 24.57 | 46.34 | -0.98 | -17.05 | |||||
Net Income, 5 Yr. CAGR % | -19.26 | 24.57 | 46.34 | -0.96 | -16.98 | |||||
Normalized Net Income, 5 Yr. CAGR % | -0.63 | 7.48 | 2.69 | 7.37 | 15.4 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -14.72 | 22.51 | 42.68 | -2.1 | -17.8 | |||||
Accounts Receivable, 5 Yr. CAGR % | 3.73 | 3.85 | 4.94 | 6.74 | 6.95 | |||||
Inventory, 5 Yr. CAGR % | 5.86 | 11.01 | 11.61 | 16.33 | 12.22 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 11.28 | 10.51 | 10.79 | 13.1 | 9.16 | |||||
Total Assets, 5 Yr. CAGR % | 11.16 | 12.24 | 11.26 | 10.84 | 5.21 | |||||
Tangible Book Value, 5 Yr. CAGR % | -34.59 | -22.77 | -25.73 | -27.18 | -15.01 | |||||
Common Equity, 5 Yr. CAGR % | 19.38 | 19.81 | 20.17 | 17.18 | 9.42 | |||||
Cash From Operations, 5 Yr. CAGR % | 16.89 | 9.61 | 1.36 | 51.85 | 13.35 | |||||
Capital Expenditures, 5 Yr. CAGR % | 8.77 | 8.06 | 13.01 | 17.61 | 11.37 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 4.64 | 2.2 | -1.54 | 28.68 | 5.22 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 4.68 | 2.55 | 0.81 | 24.51 | 3.32 |
- Stock Market
- Equities
- BSX Stock
- Financials Boston Scientific Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















